Last reviewed · How we verify
Tobramycin once a day
Tobramycin is an aminoglycoside antibiotic that binds to bacterial 30S ribosomal subunits and inhibits protein synthesis, leading to bacterial cell death.
Tobramycin is an aminoglycoside antibiotic that binds to bacterial 30S ribosomal subunits and inhibits protein synthesis, leading to bacterial cell death. Used for Serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella, Enterobacter, Serratia, Proteus, Providencia, Citrobacter), Cystic fibrosis-associated Pseudomonas aeruginosa lung infections, Gram-positive infections in combination with other antibiotics.
At a glance
| Generic name | Tobramycin once a day |
|---|---|
| Sponsor | Oslo University Hospital |
| Drug class | Aminoglycoside antibiotic |
| Target | Bacterial 30S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Tobramycin irreversibly binds to the 30S ribosomal subunit of susceptible bacteria, disrupting accurate mRNA translation and causing misreading of the genetic code. This results in production of non-functional proteins and ultimately bacterial cell death. The once-daily dosing regimen takes advantage of the concentration-dependent bactericidal activity and post-antibiotic effect of aminoglycosides.
Approved indications
- Serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella, Enterobacter, Serratia, Proteus, Providencia, Citrobacter)
- Cystic fibrosis-associated Pseudomonas aeruginosa lung infections
- Gram-positive infections in combination with other antibiotics
Common side effects
- Nephrotoxicity (acute kidney injury)
- Ototoxicity (hearing loss, tinnitus, vertigo)
- Neuromuscular blockade
- Injection site reactions
- Nausea and vomiting
Key clinical trials
- Effect of Topical Sinonasal Antibiotics (PHASE2)
- A Study of the Clinical Benefit of Tobramycin Inhalation Solution
- Platelet-rich Fibrin(PRF) Membrane in Ophthalmic Diseases (NA)
- IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy (PHASE4)
- Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections (PHASE3)
- Probiotics for Treatment of Chalazion in Adults (NA)
- Inhaled Nebulized Tobramycin in Non-cystic Fibrosis Bronchiectasis (PHASE2, PHASE3)
- Tobramycin in Bronchiectasis Colonized With Pseudmonas Aeruginosa (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tobramycin once a day CI brief — competitive landscape report
- Tobramycin once a day updates RSS · CI watch RSS
- Oslo University Hospital portfolio CI